#multiple_sclerosis
Back from #ECTRIMS2025 in Barcelona! Where Claudia Rodriguez-Lopez masterfully presented our work “Progressive demyelination, neuroinflammation and disability by brain TAF1 alteration found in #multiple_sclerosis”, selected for Best of ECTRIMS Slide Deck!
@cbm-csic-uam.bsky.social
@uam.es @csic.es
September 30, 2025 at 5:33 PM
New Study Highlights Kesimpta® Efficacy in Relapsing MS Patients Switching from Oral Therapies#United_States#Multiple_Sclerosis#Novartis#East_Hanover#Kesimpta
New Study Highlights Kesimpta® Efficacy in Relapsing MS Patients Switching from Oral Therapies
Recent findings reveal that Kesimpta® shows remarkable effectiveness in treating relapsing multiple sclerosis, especially after switching from oral therapies.
third-news.com
September 24, 2025 at 6:53 AM
Neuraxpharm Strengthens Commitment to Multiple Sclerosis at ECTRIMS 2025 in Barcelona#Spain#Barcelona#Multiple_Sclerosis#Neuraxpharm#ECTRIMS
Neuraxpharm Strengthens Commitment to Multiple Sclerosis at ECTRIMS 2025 in Barcelona
Neuraxpharm highlights its dedication to multiple sclerosis treatment at ECTRIMS 2025 in Barcelona, showcasing innovative therapies in CNS disorders.
third-news.com
September 22, 2025 at 2:54 PM
Immunic's Patent Approval Marks Milestone for Vidofludimus Calcium in Multiple Sclerosis Treatment#United_States#New_York#Multiple_Sclerosis#Immunic#Vidofludimus
Immunic's Patent Approval Marks Milestone for Vidofludimus Calcium in Multiple Sclerosis Treatment
Immunic, Inc. has secured a U.S. patent for Vidofludimus Calcium, critical for treating progressive multiple sclerosis, offering significant market protection.
third-news.com
September 9, 2025 at 10:40 AM
Immunic Presents Promising Long-Term Data on Vidofludimus Calcium for MS Patients at Phase 2 EMPhASIS Trial#USA#New_York#Multiple_Sclerosis#Immunic#Vidofludimus
Immunic Presents Promising Long-Term Data on Vidofludimus Calcium for MS Patients at Phase 2 EMPhASIS Trial
Immunic, Inc. has revealed new long-term data from the Phase 2 EMPhASIS trial for Vidofludimus Calcium, showcasing its efficacy in managing relapsing-remitting MS.
third-news.com
June 24, 2025 at 10:33 AM
So proud of Claudia Rodríguez-López for her brilliant defense of her Doctoral Thesis entitled “TAF1-dependent transcriptional dysregulation underlies multiple sclerosis”
@cbm-csic-uam.bsky.social @csic.es
@felixhernandezp.bsky.social
#esclerosis_múltiple
#multiple_sclerosis
#ciberned
June 23, 2025 at 9:57 AM
Rapid Growth of the Multiple Sclerosis Market Forecasted with a 3.8% CAGR from 2025 to 2034#None#Multiple_Sclerosis#DMTs#BTK_Inhibitors
Rapid Growth of the Multiple Sclerosis Market Forecasted with a 3.8% CAGR from 2025 to 2034
The Multiple Sclerosis market is projected to expand significantly, driven by advancements in treatment and increased prevalence, with a CAGR of 3.8% until 2034.
third-news.com
June 11, 2025 at 9:47 PM
It’s my greatest pleasure to join the Bluesky community to broaden my network, to follow the pioneers and to communicate with peers.
#Multiple_sclerosis #neurology #MS #research #MRI #fMRI
March 26, 2025 at 8:33 PM
National MS Society Introduces New Campaign to Promote Awareness and Support During MS Awareness Week#United_States#New_York#Multiple_Sclerosis#MS_Awareness#National_MS_Society
National MS Society Introduces New Campaign to Promote Awareness and Support During MS Awareness Week
The National Multiple Sclerosis Society launches the impactful 'Tell MS It Ends With Us' campaign during MS Awareness Week to engage and educate.
third-news.com
March 5, 2025 at 1:34 PM